Sexual transmission of human T-lymphotropic virus type I among female prostitutes and among patients with sexually transmitted diseases in Fukuoka, Kyushu, Japan

Am J Epidemiol. 1995 Feb 15;141(4):305-11. doi: 10.1093/aje/141.4.305.

Abstract

The authors investigated the prevalence of antibody to human T-lymphotropic virus type I (anti-HTLV-I) in 409 female prostitutes, 446 patients with an episode of sexually transmitted diseases, and 17,345 control blood donors. All subjects were Japanese and all studies were done in Fukuoka, Kyushu, Japan, in 1989. The prevalence of anti-HTLV-I was significantly higher in the prostitutes (5.1%, p < 0.001), in the male patients (2.8%, p < 0.05), and in the female patients (5.7%, p < 0.05) than in the controls (males 1.4%, females 2.2%). Prevalence of anti-HTLV-I in the prostitutes increased with the number of years spent in prostitution, but the increase was not statistically significant. Among the subjects with sexually transmitted diseases, female prostitutes with syphilis, male patients with non-gonococcal urethritis, female patients with syphilis, and female patients with gonorrhea had a significantly higher prevalence of anti-HTLV-I than did the controls. A longitudinal study was done on the 168 prostitutes. Two (1.3%) of the 158 initially seronegative subjects seroconverted over the period of 2 years. These data suggest that the risk of male-to-female transmission of HTLV-I through sexual contact is high among high risk groups in Japan, and they support the possibility of female-to-male transmission of HTLV-I.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Cross-Sectional Studies
  • Disease Transmission, Infectious*
  • Female
  • HTLV-I Antibodies / blood
  • HTLV-I Infections / complications
  • HTLV-I Infections / epidemiology
  • HTLV-I Infections / transmission*
  • Humans
  • Japan / epidemiology
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Prevalence
  • Seroepidemiologic Studies
  • Sex Work*
  • Sexual Behavior
  • Sexually Transmitted Diseases / complications*

Substances

  • HTLV-I Antibodies